BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rapirosiran (ALN-HSD) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rapirosiran (ALN-HSD)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05519475-6912@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Rapirosiran (ALN-HSD): Phase 2 readout est. (NCT05519475)
DESCRIPTION:Rapirosiran (ALN-HSD)\, phase 2\, MASH / NASH.\nStudy: A Precis
 ion Medicine Approach Using Gene Silencing to Treat a Chronic Liver Diseas
 e Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult 
 Participants at Increased Genetic Risk for This Condition\nEstimated prima
 ry completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rapirosiran-aln-hsd#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05519475
URL:https://assetmemo.bio/drug/rapirosiran-aln-hsd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
